Gustavo A. Rosario Benitez

Array ( [id] => 15496355 [patent_doc_number] => 20200048366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/282949 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844945 [patent_doc_number] => 11434298 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Antibodies to CD70 [patent_app_type] => utility [patent_app_number] => 16/278522 [patent_app_country] => US [patent_app_date] => 2019-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 24 [patent_no_of_words] => 42473 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16278522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398841 [patent_doc_number] => 20200339699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => FULLY HUMANIZED ANTI-B CELL MATURATION ANTIGEN (BCMA) SINGLE-CHAIN ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/759956 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743975 [patent_doc_number] => 20190255161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/263913 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578551 [patent_doc_number] => 20190216884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY [patent_app_type] => utility [patent_app_number] => 16/263124 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309091 [patent_doc_number] => 10519236 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Antibodies specific to delta 1 chain of T cell receptor [patent_app_type] => utility [patent_app_number] => 16/255769 [patent_app_country] => US [patent_app_date] => 2019-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 64 [patent_no_of_words] => 51743 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16255769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372477 [patent_doc_number] => 12479901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => T-cell receptor [patent_app_type] => utility [patent_app_number] => 16/961409 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 27 [patent_no_of_words] => 8563 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1026 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372477 [patent_doc_number] => 12479901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => T-cell receptor [patent_app_type] => utility [patent_app_number] => 16/961409 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 27 [patent_no_of_words] => 8563 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1026 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638092 [patent_doc_number] => 12168693 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Combining CD27 agonists and immune checkpoint inhibition for immune stimulation [patent_app_type] => utility [patent_app_number] => 16/249404 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 15581 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673112 [patent_doc_number] => 20210061875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 16/958539 [patent_app_country] => US [patent_app_date] => 2018-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158765 [patent_doc_number] => 20190106485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => ANTI FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 16/223930 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713654 [patent_doc_number] => 11377638 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Compositions and methods for TCR reprogramming using fusion proteins [patent_app_type] => utility [patent_app_number] => 16/222846 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 48 [patent_no_of_words] => 45007 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16222846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897013 [patent_doc_number] => 20190292272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/222188 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16222188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428914 [patent_doc_number] => 11674125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Glycoengineering [patent_app_type] => utility [patent_app_number] => 16/954814 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 66 [patent_no_of_words] => 21035 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117229 [patent_doc_number] => 20190345247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON [patent_app_type] => utility [patent_app_number] => 16/215496 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16215496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832163 [patent_doc_number] => 11008404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibodies to MASP-2 [patent_app_type] => utility [patent_app_number] => 16/209255 [patent_app_country] => US [patent_app_date] => 2018-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17283 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16209255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832163 [patent_doc_number] => 11008404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibodies to MASP-2 [patent_app_type] => utility [patent_app_number] => 16/209255 [patent_app_country] => US [patent_app_date] => 2018-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17283 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16209255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650021 [patent_doc_number] => 10927184 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Treatment of cancer using humanized anti-CD19 chimeric antigen receptor [patent_app_type] => utility [patent_app_number] => 16/192375 [patent_app_country] => US [patent_app_date] => 2018-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 57139 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16192375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411788 [patent_doc_number] => 12077595 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Single domain antibodies that bind to CD137 [patent_app_type] => utility [patent_app_number] => 16/763059 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 7 [patent_no_of_words] => 28796 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 3247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926383 [patent_doc_number] => 20190298829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => PURIFIED ANTIBODY COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/184374 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16184374 [rel_patent_id] =>[rel_patent_doc_number] =>)